

EFFICACY AND TOLERABILITY OF A NEW DERMO-COSMETIC SERUM CONTAINING MYRTUS COMMUNIS AND CELASTROL ENRICHED EXTRACTS, AZELAIC AND GLYCOLIC ACIDS, IN MILD TO MODERATE ADULT FEMALE ACNE

L. Alies¹, V. Mengeaud², A. Philippe¹, M.D. Thouvenin¹
¹R&D Department Pierre Fabre Dermo-Cosmétique et Personal Care, Toulouse, France
²Medical Department, Laboratoires Dermatologiques DUCRAY, Lavalur, France

P0102

INTRODUCTION

Adult female acne and its significant impact on the quality of life are increasingly recognized. Hormonal factors are one of its specific features and flare-ups before menstruation are observed in about half of adult patients with acne.
The aim of this clinical study was to assess the efficacy and tolerance of a new dermo-cosmetic serum, containing *Myrtus communis* and Celastrol enriched extracts, azelaic and glycolic acids, dedicated to adult female acne.

MATERIAL & METHODS

POPULATION

33 female subjects
aged 18-38 years old
included in a 8 week open clinical study

VISITS

D1, D8, D29, D57

FREQUENCY OF APPLICATION

2 applications a day
(morning and evening)

MAIN INCLUSION CRITERIA


- Mild to moderate acne according to Global Acne Evaluation (GEA) scale, with:
 - a total of 15 to 50 total acne lesions
 - at least 10 non-inflammatory lesions (open and closed comedons)
 - at least 5 inflammatory lesions (papules and pustules)
- Subjects having acne fluctuations linked to menstrual cycle

ASSESSMENTS

- ✓ **Acne severity**
 - Acne lesions counting according Lucky method
 - Global acne assessment (GEA)
 - Global acne assessment by subjects
 - “Acne flare-up” severity during menstrual cycle (subject self-assessment) – 10-point scale
- ✓ **Post-Inflammatory Erythema (PIE) and Hyperpigmentation (PIH)**
 - Surface according to photograph analysis (target lesions)
 - Global assessment by Investigator
- ✓ **Sebum secretion**
 - Sebaceous secretion evaluation by Sebutape® . number + total surface occupied by the sebum spots
- ✓ **Quality of life**
 - Cardiff Acne Disability Index (CADI) questionnaire
- ✓ **Cosmetic acceptability questionnaire**
- ✓ **Tolerability**
- ✓ **Standardized photographs**

RESULTS

ACNE SEVERITY



At D57,
. Significant decrease of non inflammatory lesions: -47% ($p \leq 0.001$)
and inflammatory lesions: -58% ($p \leq 0.001$)
. Significant improvement of GEA: -27% ($p \leq 0.001$)
. Acne global improvement for 88% of subjects






Photo credits: Pierre Fabre Dermo-Cosmetique / Illustration of a mean case (female subject, 27 years old, with a mild GEA score on D1)

ACNE FLARE-UP RELATED TO MENSTRUAL CYCLE




At D57,
78% subjects find their acne flare-up reduced during their last menstrual cycle

POST INFLAMMATORY LESIONS



At D57,
. Significant decrease of PIE surface: -67% ($p \leq 0.001$) and PIH surface: -62% ($p \leq 0.001$)
. Product judged as effective by the Investigator on PIE in 76% of subjects and on PIH in 75% of subjects

SEBUM SECRETION



From D8, significant reduction of sebum secretion ($p \leq 0.001$)

CONCLUSION

Efficacy results of this new dermo-cosmetic serum highlight the potential benefit of this product as complementary care in adult females with mild to moderate acne and prone to acne-flare-ups related menstrual cycle. The good tolerance, the improvement of the quality of life and the cosmetic qualities and perceived efficacy of the serum could ensure a good observance in the management of acne.

Quality of life: from D29, a significant improvement of the quality of life (CADI score) was observed ($p \leq 0.001$).

Cosmetic acceptability: cosmetic qualities and efficacy of the product were appreciated by the subjects.

Tolerability: cutaneous tolerance was assessed as good by the dermatologist. Functional and/or physical signs were mainly of mild intensity and occurred at the beginning of the study.